Ëàâëàãàà
1. Í. Íàðàíáàò áà
áóñàä "Ìîíãîë óëñàä á¿ðòãýãäñýí áàéãàà õ¿íèé õàëäâàðò ºâ÷íèé ºíãºðñºí, îäîî,
èðýýä¿éí òºëºâ áàéäàë”, ÓÁ õîò, 2008 îí, õóóäàñ 8-12
2.
ÄÝÌÁ "Çîíõèëîí òîõèîëääîã õàëäâàðò ºâ÷íèé òàíäàëò” ÓÁ
õîò, 2004 îí, õóóäàñ 47-49
3.
ß.Äàãâàäîðæ íàð "Õàëäâàðò ºâ÷èí” ÓÁ õîò, 2003 îí, õóóäàñ
141-148
4.
Á.Ãàíáààòàð "Àíàãààõ óõààíû áè÷èë àìü ñóäëàë” ÓÁ õîò,
2009 îí, õóóäàñ 193-197
5. ÕªÑ¯Ò "Õàëäâàðò
ºâ÷íèé òóëãàìäñàí àñóóäàë” èëòãýëèéí õóðààíãóé, Óª õîò, 2008 îí, õóóäàñ 19-22
References
1. Pollard AJ, Nadel S, Ninis N, Faust SN,
Levin M. Emergency management of meningococcal disease: eight years
on. Arch Dis Child. Apr 2007;92(4):283-6. [Medline].
2. Pathan N, Faust SN, Levin
M. Pathophysiology of meningococcal meningitis and septicaemia. Arch
Dis Child. Jul 2003;88(7):601-7. [Medline].
3. Faust SN, Levin M, Harrison OB, et
al. Dysfunction of endothelial protein C activation in severe
meningococcal sepsis. N Engl J Med. Aug
9 2001;345(6):408-16. [Medline].
4. Pathan N, Hemingway CA, Alizadeh AA,
et al. Role of interleukin 6 in myocardial dysfunction of meningococcal
septic shock. Lancet. Jan 17 2004;363(9404):203-9. [Medline].
5. Pathan N, Williams EJ, Oragui EE,
Stephens AC, Levin M. Changes in the interleukin-6/soluble interleukin-6
receptor axis in meningococcal septic shock. Crit Care Med. Aug 2005;33(8):1839-44. [Medline].
6. El Bashir H, Laundy M, Booy
R. Diagnosis and treatment of bacterial meningitis. Arch Dis Child. Jul 2003;88(7):615-20. [Medline].
7. Ortega-Sanchez IR, Meltzer MI,
Shepard C, et al. Economics of an adolescent meningococcal conjugate
vaccination catch-up campaign in the United States. Clin Infect Dis. Jan
1 2008;46(1):1-13. [Medline].
8. Health Protection Agency. Invasive
meningococcal infections, England and Wales, laboratory reports: weeks
51-52/2007. http://hpa.org.uk: 2008. [Full Text].
9. Welch SB, Nadel S. Treatment of
meningococcal infection. Arch Dis Child. Jul 2003;88(7):608-14. [Medline].
10. Jansen AG, Sanders EA, VAN DER Ende
A, et al. Invasive pneumococcal and meningococcal disease: association
with influenza virus and respiratory syncytial virus activity?. Epidemiol
Infect. Nov 2008;136(11):1448-54. [Medline].
11. Faber J, Henninger N, Finn A, Zenz
W, Zepp F, Knuf M. A toll-like receptor 4 variant is associated with fatal
outcome in children with invasive meningococcal disease. Acta Paediatr. Mar 2009;98(3):548-52. [Medline].
12. Darton T, Guiver M, Naylor S, Jack
DL, Kaczmarski EB, Borrow R. Severity of meningococcal disease associated
with genomic bacterial load. Clin Infect Dis. Mar
1 2009;48(5):587-94. [Medline].
13. [Guideline] Health Protection
Agency. Guidance for the public health management of meningococcal disease
in the UK. [Full Text].
14. Food and Drug Administration. Ceftriaxone
(marketed as Rocephin) information. 2008. [Full Text].
15. Roche. Important clarification
of prescribing information. Contraindications. http://www.rocheusa.com. Available
at http://www.rocheusa.com/products/rocephin/rocephin-hcp-letter.pdf. Accessed August 5, 2008.
16. Medicines and healthcare products
regulatory agency. Ceftriaxone; incompatibility with calcium containing
solutions. http://www.nelm.nhs.uk/en/: 2008.
17. Food and Drug Administration. Ceftriaxone
(marketed as Rocephin) Information. http://www.fda.gov: April
2009. [Full Text].
18. Cathie K, Levin M, Faust
SN. Drug use in acute meningococcal disease. Arch Dis Child Educ
Pract Ed. Oct 2008;93(5):151-8. [Medline].
19. Levin M, Quint PA, Goldstein B, et
al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as
adjunctive treatment for children with severe meningococcal sepsis: a
randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. Sep
16 2000;356(9234):961-7. [Medline].
20. Derkx B, Wittes J, McCloskey
R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal
antibody to endotoxin, in children with meningococcal septic shock. European Pediatric
Meningococcal Septic Shock Trial Study Group. Clin Infect Dis. Apr 1999;28(4):770-7. [Medline].
